P: 404.221.0617
Fax: 404.448.3982
Email: admin@gabio.org
Address: 999 Peachtree Street NE #1800, Atlanta, GA 30309
Introducing the Georgia Life Sciences Podcast
Introducing the Georgia Life Sciences Podcast, a valuable resource for entrepreneurs, investors, policymakers, and anyone interested in learning more about Georgia's role in the life sciences industry.
The episodes typically cover a range of topics such as:
- Interviews with Industry Leaders: Conversations with experts, entrepreneurs, and executives from life sciences companies who are driving innovation and growth in Georgia.
- Emerging Trends: Exploration of new technologies, research breakthroughs, and trends that are impacting the life sciences sector, such as biotech, pharmaceuticals, medtech, and healthcare.
- State Initiatives and Policies: Discussions on government and economic development programs, partnerships, and policies aimed at fostering the growth of the life sciences industry in Georgia.
- Success Stories: Spotlighting successful startups, research institutions, and collaborations that are helping put Georgia on the map as a leader in life sciences.
Season one episodes will be featured bi-weekly in the BioBeat Newsletter or can be downloaded here.
The Georgia Life Sciences Podcast is ideal for anyone looking to stay informed about Georgia's evolving life sciences landscape and learn about opportunities for growth, investment, and collaboration in this exciting field. Sponsorship opportunities available. Please contact Stacey Bowlin, sbowlin@galifesciences.org, to learn more.
Georgia Life Sciences Association Statement on the Release of the NSCEB Final Report and Action Plan
Emerging biotechnology is key for U.S. to remain dominant and secure future economic growth in a new era of global competition
The recent U.S. tariff announcement has sent ripples through the life sciences, biotech, and MedTech industries, raising concerns about its potential impact on innovation, manufacturing, and global supply chains. While some sectors, such as pharmaceuticals, have been temporarily exempt from these new tariffs, the uncertainty surrounding future trade policies remains a significant challenge for our industry. These tariffs—set to take effect on April 5—include a base 10% tariff on all countries, with reciprocal tariffs reaching up to 50% on certain nations. There are growing concerns that these measures could increase costs for life-saving medical technologies, disrupt supply chains, and hinder job growth. Additionally, the agricultural biotech sector will likely be affected immediately, particularly with higher tariffs on non-USMCA-compliant goods. Pharmaceuticals, while currently exempt, may face their own tariffs in the near future, pending a potential Section 232 investigation into pharmaceutical manufacturing and national security. Georgia’s life sciences ecosystem thrives on innovation, investment, and global collaboration. Our industry depends on stable, predictable trade policies that support growth, not policies that introduce uncertainty and additional financial burdens. We must ensure that trade policies protect patients, support manufacturers, and sustain the broader biotech and MedTech economy. Georgia Life Sciences will continue to monitor these developments in partnership with our national associations and work closely with our members and policymakers to ensure our industry’s voice is heard. We encourage our community to stay engaged and share any concerns about how these tariffs may impact your businesses, workforce, and supply chains. For questions or to provide input on how these policies affect your organization, please reach out to our team.
In a coordinated effort on the national stage, Georgia Life Sciences is joining forces with 47 other state biotechnology associations under the Council of State Biosciences Associations (CSBA) umbrella to urge congressional action on research and development tax amortization legislation. The coalition has sent a formal letter to congressional leadership calling for the immediate passage of the American Innovation and R&D Competitiveness Act (H.R. 1990), bipartisan legislation sponsored by Representatives Ron Estes (D-KS) and John Larson (R-CT). The bill aims to repeal harmful research and amortization provisions that went into effect in 2022 under the Tax Cuts and Jobs Act. Georgia Life Sciences representatives are heading to Washington DC this week alongside fellow CSBA members to meet directly with Georgia legislators. The group will advocate for this critical tax reform, which would restore immediate expensing of R&D expenditures rather than requiring companies to amortize these deductions over five years for domestic expenditures or 15 years for foreign expenditures. The current mandatory amortization requirements are "already diverting much-needed funds away from small R&D-intensive companies, potentially jeopardizing the development of future treatments and negatively impacting the local economies where these companies are established," according to the CSBA letter. During their Capitol Hill visits, the Georgia Life Sciences delegation will also address other pressing issues facing Georgia’s life sciences community while emphasizing the importance of supporting innovation in an industry dominated by pre-revenue companies developing critical medical breakthroughs.
P: 404.221.0617
Fax: 404.448.3982
Email: admin@galifesciences.org
Address: 8607 Roberts Drive, Suite 250, Atlanta, GA 30350
